Roche, Plexxikon to develop, commercialize PLX4032

SarahTurner

LONDON (MarketWatch) -- Swiss pharmaceutical Roche
rhhdy
said Thursday that it has signed a development and commercialization deal with Plexxikon Inc. for PLX4032, Plexxikon's investigational targeted cancer therapy which selectively inhibits B-RafV600E, a mutated form of the BRAF kinase gene. Plexxikon filed an Investigational New Drug application for PLX4032 in September 2006, and plans to initiate a phase 1 clinical trial by the end of this year. Separately, Roche Molecular Diagnostics, a business unit of Roche Diagnostics, and Plexxikon announced they will collaborate on development of an in vitro assay to screen for the presence of the BRAFV600E mutation in biological samples taken from patient tumors.

Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.